Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 8, 2001 - Issue 4
64
Views
24
CrossRef citations to date
0
Altmetric
Original Article

Characterization of cholyl-leu-val-phe-phe-ala-OH as an inhibitor of amyloid beta-peptide polymerization

, , , , , , & show all
Pages 231-241 | Received 11 Dec 2000, Accepted 02 Apr 2001, Published online: 04 Aug 2009
 

Abstract

Cholyl-LVFFA-OH (1, PPI-368) is an organic-modified peptide based on the sequence of amyloid beta-peptide (Aβ). It is a potent and selective inhibitor of A β polymerization that blocks the formation of neurotoxic species of Aβ. In a nucleation-dependent polymerization assay of 50μM Aβ1-40 equimolar concentrations of PPI-368 block polymerization based on turbidity and electron microscopy. Monomeric Aβ1-40 and Aβ1-42 are non-toxic when incubated with neuronal cell lines, but become toxic during polymerization. PPI-368 coordinately delays the onset of polymerization and the formation of neurotoxic Aβ species for both peptides. In a polymerization extension assay seeded with pre-formed Aβ polymer, similar inhibition and dose-dependency phenomena are observed with PPI-368. Radiolabeled PPI-368 is incorporated into fibrils during polymerization demonstrating binding to Aβ peptide within a fibrillar structure. Gel-filtration studies show progressive disappearance of Aβ monomer and concomitant appearance of soluble higher molecular weight oligomers. In the presence of submolar concentrations of PPI-368, monomeric Aβ is still present and oligomers are not observed. PPI-368 does not inhibit the polymerization of other amyloidogenic proteins such as transthyretin (TTR) or islet amyloid polypeptide(IAPP20-29).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.